This update provides new baseline risk estimates for hospital admission for non-severe COVID-19 patients.

The revised estimates aid healthcare professionals in identifying and tailoring treatment for individuals based on their risk levels.

The most notable change includes the transition of individuals over 65 and those with specific chronic conditions from high to moderate risk.

WHO reiterates its strong endorsement of Nirmatrelvir-Ritonavir ('Paxlovid').

WHO recommends molnupiravir or remdesivir in cases where Nirmatrelvir-Ritonavir is unavailable for high-risk patients.

Further, it advises against molnupiravir and remdesivir for moderate risk due to potential harms outweighing benefits.

Only symptomatic treatment is recommended for low-risk patients.

WHO cautions against routine use of new antivirals (VV116) and strongly opposes ivermectin for non-severe COVID-19, restricting its usage to clinical trials in severe or critical cases.